The Food and Drug Administration (FDA) has submitted a proposed cannabis products enforcement policy to the White House for review that concerns regulatory issues specifically related to CBD.
The White House Office of Management and Budget’s (OMB) Office of Information and Regulatory Affairs (OIRA) posted a notice that it received the submission from FDA, which falls under the U.S. Department of Health and Human Services (HHS), on Friday.
While the update doesn’t include the text of the proposal that’s now under OIRA review, it’s titled “Cannabidiol (CBD) Products Compliance and Enforcement Policy.”
The fact that the document is coming from FDA may shed light on its content, as the agency recently missed a congressional imposed deadline to publish a list of known cannabinoids as federal hemp laws are set to change later this year.
Another possibility that’s being floated by industry observers is that it ties back to an executive order on marijuana rescheduling President Donald Trump signed in December that contained provisions on providing federal health insurance coverage of CBD for certain patients. But that rulemaking is being facilitated by the Centers for Medicare & Medicaid Services (CMS), which is not listed as the agency that submitted the proposal
Read full article on Marijuana Moment
